Posted by Michael Wonder on 17 Nov 2021
European Commission approves Nucala (mepolizumab) in three additional eosinophil-driven diseases
17 November 2021 - Approval for the first targeted treatment for eosinophilic granulomatosis with polyangiitis and the first anti-IL-5 biologic treatment for patients with hypereosinophilic syndrome or chronic rhinosinusitis with nasal polyps in Europe.
GlaxoSmithKline today announced that the European Commission has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5, for use in three additional eosinophil-driven diseases.
